Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
X-rays illuminate the mechanism used by HIV to attack human DNA

Scientists from Imperial College London have used data collected at Diamond Light Source, the UK’s national synchrotron facility, to advance the understanding of how HIV and other retroviruses infect human or animal cells.

Published
11 November 2010
From
Imperial College London
FDA Okays First Drug for Lipodystrophy

The FDA has approved the first drug for treatment of HIV patients with lipodystrophy, a condition associated with antiretroviral therapy.

Published
11 November 2010
From
MedPage Today HIV/AIDS
Workshop report: “Towards a Cure: HIV Reservoirs and Strategies to Control Them”

Immediately prior to the XVIII International AIDS Conference in Vienna, Austria, the International AIDS Society held a workshop on the important topic of moving beyond antiretroviral therapy and addressing HIV persistence. This article gives an overview of the findings presented at the workshop; complete abstracts are included in this supplement to the Journal of the International AIDS Society.

Published
04 November 2010
From
Journal of International AIDS Society
Crofelemer ADVENT trial demonstrates highly statistically significant results in the treatment of HIV-associated diarrhea

In this study, crofelemer provided relief of diarrhea for a highly statistically significant proportion of patients compared to placebo. Crofelemer is a first-in-class, naturally occurring, gut-targeted, oral anti-secretory, anti-diarrheal agent that has minimal absorption.

Published
04 November 2010
From
Market Watch
Bristol-Myers, Gilead seek AIDS cocktail success in hepatitis C

Bristol-Myers Squibb Co. and Gilead Sciences Inc., makers of the top-selling combination pills for AIDS, are trying to duplicate their success to combat another evasive virus, hepatitis C. The companies are among about a dozen that are developing drug cocktails more effective, less toxic and easier to take than current therapy.

Published
30 October 2010
From
Bloomberg
How we fix America’s dated drug approval process

As the national debate continues to rage about health reform, there is a window of opportunity to help millions of patients treat chronic illnesses such as cancer, diabetes and HIV/AIDS.

Published
28 October 2010
From
The Hill
IDSA: Cancer Gene Plays Key Role in HIV Infection (CME/CE)

A gene formerly known as a tumor suppressor may play a role in a so-called "functional cure" for HIV, a researcher said here.

Published
22 October 2010
From
MedPage Today HIV/AIDS
Shionogi-ViiV Healthcare begin two phase III studies for investigational once-daily HIV integrase inhibitor

The once-daily integrase inhibitor will be studied in comparison with raltegravir in two studies, one in treatment-naive and the other in treatment-experienced patients.

Published
21 October 2010
From
Market Watch
Cytheris Announces Initiation of ORVACS-Sponsored Phase II Clinical Study to Attack Viral Reservoir of HIV Patients

By combining an integrase inhibitor and a CCR5 inhibitor with IL-7 to target or induce activation of latently infected cells, study aims to investigate whether exhausting the HIV reservoir and ultimately obtaining virus eradication is feasible.

Published
19 October 2010
From
Reuters
NeurogesX to pursue expanded U.S. label for Qutenza® (capsaicin) 8% patch in HIV-associated neuropathy

NeurogesX, a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced plans to pursue a U.S. label expansion for Qutenza® (capsaicin) 8% patch to include patients with painful HIV-associated neuropathy (HIV-AN, also referred to as HIV-distal sensory polyneuropathy (HIV-DSP)).

Published
18 October 2010
From
PR Newswire

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.